• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases.

作者信息

Carey Patricia, Pardanani Animesh, Starlinger Patrick, Tefferi Ayalew, Gangat Naseema

机构信息

Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Am J Hematol. 2025 Mar;100(3):527-530. doi: 10.1002/ajh.27570. Epub 2024 Dec 26.

DOI:10.1002/ajh.27570
PMID:39723660
Abstract
摘要

相似文献

1
Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases.JAK2抑制剂治疗的骨髓纤维化患者脾切除的结果：梅奥诊所34例连续病例的经验
Am J Hematol. 2025 Mar;100(3):527-530. doi: 10.1002/ajh.27570. Epub 2024 Dec 26.
2
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
3
One thousand patients with essential thrombocythemia: the Mayo Clinic experience.一千例原发性血小板增多症患者：梅奥诊所的经验。
Blood Cancer J. 2024 Jan 18;14(1):11. doi: 10.1038/s41408-023-00972-x.
4
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.骨髓增殖性疾病中细胞因子信号传导抑制因子3基因（SOCS3）的甲基化
Haematologica. 2008 Nov;93(11):1635-44. doi: 10.3324/haematol.13043. Epub 2008 Sep 24.
5
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.真性红细胞增多症、原发性骨髓纤维化和原发性血小板增多症中的细胞遗传学、JAK2和MPL突变
Rev Bras Hematol Hemoter. 2011;33(6):417-24. doi: 10.5581/1516-8484.20110116.
6
Thrombotic incidents in patients with myelofibrosis suggest to be independent of V617f mutational status.骨髓纤维化患者的血栓事件提示与 V617f 突变状态无关。
Folia Med (Plovdiv). 2022 Aug 31;64(4):655-660. doi: 10.3897/folmed.64.e72175.
7
Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.接受异基因干细胞移植的骨髓纤维化患者在接受JAK1/JAK2抑制剂治疗后行脾切除术。
Hematol Oncol Stem Cell Ther. 2019 Sep;12(3):140-145. doi: 10.1016/j.hemonc.2019.03.001. Epub 2019 Apr 6.
8
Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.姑息治疗目标、患者选择及围手术期血小板管理：梅奥诊所30年骨髓纤维化伴髓外化生脾切除术的结果与经验教训
Cancer. 2006 Jul 15;107(2):361-70. doi: 10.1002/cncr.22021.
9
[Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].骨髓增殖性肿瘤患者JAK2突变与血栓形成的相关性研究
Zhonghua Xue Ye Xue Za Zhi. 2010 Sep;31(9):590-3.
10
JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.232例慢性骨髓增殖性肿瘤患者的JAK2 V617F突变状态
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):525-33. doi: 10.1016/j.clml.2014.02.013. Epub 2014 Mar 5.

引用本文的文献

1
Splenectomy in Onco-Hematologic Patients: A Retrospective Study of Early Complications and 1-Year Mortality.肿瘤血液学患者的脾切除术：早期并发症和1年死亡率的回顾性研究
Cancers (Basel). 2025 Jul 4;17(13):2241. doi: 10.3390/cancers17132241.
2
Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.阿那格雷在原发性血小板增多症治疗中的应用：一项系统评价和荟萃分析。
Int J Hematol. 2025 Mar 9. doi: 10.1007/s12185-025-03959-5.